The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century

ABSTRACT Matrix-M™ adjuvant is a key component of several novel vaccine candidates. The Matrix-M adjuvant consists of two distinct fractions of saponins purified from the Quillaja saponaria Molina tree, combined with cholesterol and phospholipids to form 40-nm open cage-like nanoparticles, achieving potent adjuvanticity with a favorable safety profile. Matrix-M induces early activation of innate immune cells at the injection site and in the draining lymph nodes. This translates into improved magnitude and quality of the antibody response to the antigen, broadened epitope recognition, and the induction of a Th1-dominant immune response. Matrix-M-adjuvanted vaccines have a favorable safety profile and are well tolerated in clinical trials. In this review, we discuss the latest findings on the mechanisms of action, efficacy, and safety of Matrix-M adjuvant and other saponin-based adjuvants, with a focus on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subunit vaccine candidate NVX-CoV2373 developed to prevent coronavirus disease 2019 (COVID-19).

[1]  N. Patel,et al.  Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373 , 2023, The New England journal of medicine.

[2]  H. Tinto,et al.  Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. , 2022, The Lancet. Infectious diseases.

[3]  N. Patel,et al.  Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates , 2022, Vaccines.

[4]  Dalia Zakaria,et al.  Anaphylaxis and Related Events Following COVID‐19 Vaccination: A Systematic Review , 2022, Journal of clinical pharmacology.

[5]  A. Sette,et al.  Humoral and cellular immune memory to four COVID-19 vaccines , 2022, Cell.

[6]  G. Adema,et al.  Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation , 2022, Cellular and Molecular Life Sciences.

[7]  Q. Sattentau,et al.  Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses , 2022, Frontiers in Immunology.

[8]  R. Urbanowicz,et al.  Inflammasome Contribution to the Activation of Th1, Th2, and Th17 Immune Responses , 2022, Frontiers in Microbiology.

[9]  D. Longo,et al.  Addressing Vaccine Inequity - Covid-19 Vaccines as a Global Public Good. , 2022, The New England journal of medicine.

[10]  Sa'ad Laws,et al.  Cardiovascular and haematological events post COVID‐19 vaccination: A systematic review , 2021, Journal of cellular and molecular medicine.

[11]  D. Irvine,et al.  A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity , 2021, Science Immunology.

[12]  L. Corey,et al.  Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico , 2021, medRxiv.

[13]  Bin Zhou,et al.  Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial. , 2021, The Lancet. Infectious diseases.

[14]  Sang-Soo Lee,et al.  Recent developments and strategies of Ebola virus vaccines. , 2021, Current opinion in pharmacology (Print).

[15]  P. Kalra,et al.  Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.

[16]  D. Moodley,et al.  Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant , 2021, The New England journal of medicine.

[17]  O. Traoré,et al.  Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial , 2021, The Lancet.

[18]  Jialu Zhang,et al.  COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations , 2021, Frontiers in Immunology.

[19]  N. Patel,et al.  SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice , 2021, Nature Communications.

[20]  H. Hammad,et al.  CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01 , 2021, Frontiers in Immunology.

[21]  M. Cascella,et al.  Features, Evaluation, and Treatment of Coronavirus , 2020 .

[22]  V. Shinde,et al.  Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine , 2020, The New England journal of medicine.

[23]  M. Slaoui,et al.  Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach. , 2020, The New England journal of medicine.

[24]  N. Patel,et al.  NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge , 2020, bioRxiv.

[25]  S. K. Fehling,et al.  A Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein (EBOV GP) Nanoparticle Vaccine with Matrix-M™ Adjuvant in Healthy Adults. , 2019, The Journal of infectious diseases.

[26]  E. Elinav,et al.  Inflammasome activation and regulation: toward a better understanding of complex mechanisms , 2020, Cell Discovery.

[27]  Bin Zhou,et al.  Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M–Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine , 2020, medRxiv.

[28]  S. Chaudhury,et al.  A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses , 2020, eLife.

[29]  M. Gore,et al.  Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma , 2020, Journal for ImmunoTherapy of Cancer.

[30]  N. Lurie,et al.  Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.

[31]  Shibo Jiang,et al.  Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine , 2020, Cellular & Molecular Immunology.

[32]  Z. Beck,et al.  Army Liposome Formulation (ALF) family of vaccine adjuvants , 2020, Expert review of vaccines.

[33]  V. Shinde,et al.  Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA , 2020, Vaccines.

[34]  O. Levy,et al.  Toward precision adjuvants: optimizing science and safety , 2020, Current opinion in pediatrics.

[35]  J. Ting,et al.  The NLRP3 inflammasome: molecular activation and regulation to therapeutics , 2019, Nature Reviews Immunology.

[36]  M. Lacaille‐Dubois.  Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review☆ , 2019, Phytomedicine.

[37]  J. Weiss,et al.  Quillaja Saponin Characteristics and Functional Properties. , 2019, Annual review of food science and technology.

[38]  Francini Pereira da Silva,et al.  Saponins from Quillaja saponaria and Quillaja brasiliensis: Particular Chemical Characteristics and Biological Activities , 2019, Molecules.

[39]  Adriana Baz Morelli,et al.  A Novel Cellular Pathway of Antigen Presentation and CD4 T Cell Activation in vivo , 2018, Front. Immunol..

[40]  S. Jameson,et al.  Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? CD8 T-Cell Vaccines: To B or Not to B? , 2018, Cold Spring Harbor perspectives in biology.

[41]  Sven Burgdorf,et al.  Current Concepts of Antigen Cross-Presentation , 2018, Front. Immunol..

[42]  V. Shinde,et al.  Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine. , 2018, The New England journal of medicine.

[43]  D. Marciani.  Elucidating the Mechanisms of Action of Saponin-Derived Adjuvants. , 2018, Trends in pharmacological sciences.

[44]  G. Rimmelzwaan,et al.  Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice , 2018, Immunologic research.

[45]  H. Ikematsu,et al.  Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older , 2018, The Journal of infectious diseases.

[46]  Roberto A. Maldonado,et al.  Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance , 2018, Front. Immunol..

[47]  F. Destefano,et al.  Vaccine‐associated hypersensitivity , 2018, The Journal of allergy and clinical immunology.

[48]  A. Fauci,et al.  Chasing Seasonal Influenza - The Need for a Universal Influenza Vaccine. , 2018, The New England journal of medicine.

[49]  N. Patel,et al.  Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes. , 2017, Vaccine.

[50]  R. A. van den Berg,et al.  Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity , 2017 .

[51]  C. Fossum,et al.  Innate immune responses induced by the saponin adjuvant Matrix-M in specific pathogen free pigs , 2017, Veterinary Research.

[52]  A. Hill,et al.  Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine , 2017, Scientific Reports.

[53]  M. Frieman,et al.  MERS-CoV spike nanoparticles protect mice from MERS-CoV infection , 2017, Vaccine.

[54]  T. Reinheckel,et al.  Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21 , 2017, Front. Immunol..

[55]  A. Didierlaurent,et al.  Adjuvant system AS01: helping to overcome the challenges of modern vaccines , 2017, Expert review of vaccines.

[56]  D. Lema,et al.  An Updated Review of ISCOMSTM and ISCOMATRIXTM Vaccines. , 2016, Current pharmaceutical design.

[57]  G. Adema,et al.  Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation , 2016, Nature Communications.

[58]  Bin Zhou,et al.  Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. , 2016, Vaccine.

[59]  Shixia Wang,et al.  Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants* , 2015, The Journal of Biological Chemistry.

[60]  G. Glenn,et al.  ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. , 2015, Vaccine.

[61]  N. Garçon,et al.  Vaccine Adjuvants: from 1920 to 2015 and Beyond , 2015, Vaccines.

[62]  B. Lambrecht,et al.  Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells , 2014, The Journal of Immunology.

[63]  R. Cox,et al.  Matrix MTM adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4+ T cell responses in man , 2014, Human vaccines & immunotherapeutics.

[64]  M. Frieman,et al.  Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice , 2014, Vaccine.

[65]  S. Koernig,et al.  Inflammasome-Dependent and -Independent IL-18 Production Mediates Immunity to the ISCOMATRIX Adjuvant , 2014, The Journal of Immunology.

[66]  Justin M. Richner,et al.  Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice. , 2014, Vaccine.

[67]  G. Glenn,et al.  A recombinant viruslike particle influenza A (H7N9) vaccine. , 2013, The New England journal of medicine.

[68]  S. Reed,et al.  Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.

[69]  K. Karlsson,et al.  Matrix-M™ adjuvant: enhancing immune responses by ‘setting the stage’ for the antigen , 2013, Expert review of vaccines.

[70]  W. Robinson,et al.  Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. , 2013, Vaccine.

[71]  K. Karlsson,et al.  Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice. , 2013, Vaccine.

[72]  C. Fossum,et al.  Global transcriptional response to ISCOM-Matrix adjuvant at the site of administration and in the draining lymph node early after intramuscular injection in pigs. , 2012, Developmental and comparative immunology.

[73]  K. Karlsson,et al.  Matrix-M™ Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of Antigen , 2012, PloS one.

[74]  R. Cox,et al.  T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. , 2012, The Journal of infectious diseases.

[75]  R. Cox,et al.  Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. , 2011, Vaccine.

[76]  S. Koernig,et al.  ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T Cells , 2011, The Journal of Immunology.

[77]  Bror Morein,et al.  ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation , 2011, Expert Review of Vaccines.

[78]  R. Cox,et al.  Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. , 2009, Vaccine.

[79]  M. Houghton,et al.  Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers , 2009, Human vaccines.

[80]  E. Maraskovsky,et al.  ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines , 2007, Expert review of vaccines.

[81]  Mark Shackleton,et al.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[82]  K. Schroder,et al.  Interferon- : an overview of signals, mechanisms and functions , 2004 .

[83]  F. Ennis,et al.  Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. , 2001, Vaccine.

[84]  B. Morein,et al.  Functional aspects of iscoms , 1998, Immunology and cell biology.

[85]  S. Akira,et al.  Defective NK cell activity and Th1 response in IL-18-deficient mice. , 1998, Immunity.

[86]  C. Kensil,et al.  Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. , 1991, Journal of immunology.

[87]  B. Morein,et al.  The requirement of lipids for the formation of immunostimulating complexes (iscoms) , 1988, Biotechnology and applied biochemistry.

[88]  C. Fox,et al.  Vaccine Adjuvants , 2017, Methods in Molecular Biology.

[89]  J. Baum,et al.  HIGH LEVEL EFFICACY IN HUMANS OF A NEXT-GENERATION PLASMODIUM FALCIPARUM ANTI-SPOROZOITE VACCINE: R21 IN MATRIX-M (TM) ADJUVANT , 2017 .

[90]  K. Schroder,et al.  Interferon-gamma: an overview of signals, mechanisms and functions. , 2004, Journal of leukocyte biology.

[91]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.